ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 472

Quality Assessment in Clinical Management of Patients with Rheumatoid Arthritis. Are We Using the “Treat to Target” Strategy?

Jose Luis Andreu1,2, Maria Auxiliadora Martin3, H Corominas4, Jose Javier Perez Venegas5, Jose Andres Roman Ivorra6,7, Angel Gil8, Fernando Sánchez-Alonso9, Tamara Jiménez10 and Miguel Angel Sánchez-Ruiz10, 1Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain, 2Rheumatology, HU Puerta de Hierro Majadahonda, Madrid, Spain, 3Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, 4CapiCAT group (Nailfold Capillaroscopy group from the Catalan Society for Rheumatology)., Catalonia, Spain, 5Rheumatology, Hospital de Jerez de la Frontera, Jerez de la Frontera, Spain, 6Rheumatology, H.U. P. La Fe, Valencia, Spain, 7Servicio de Reumatología, Servicio de Reumatología Hospital Universitario La Fe, Valencia, Spain, 8Cátedra de Resultados en Salud, Universidad Rey Juan Carlos, Madrid, Spain, 9Unidad de Investigación. Sociedad Española de Reumatología, Madrid, Spain, 10Universidad Rey Juan Carlos, Madrid, Spain

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Benchmarking tools, Best practices, management, rheumatoid arthritis (RA) and treatment guidlelines

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

The current paradigm of optimal clinical management of patients with rheumatoid arthritis (RA) recommends reaching a state of remission or low activity of the disease, assessed by composite indexes of activity, by means of a tight control and a dynamic adjustment of available therapeutic options, using a “treat to target” strategy. The aim of this work is to assess the level of implementation of the “treat to target” strategy and other parameters of medical quality in clinical records (CRs) of RA patients in Spanish rheumatology departments.

Methods:

Adult RA patients fulfilling 2010 ACR-EULAR criteria for RA and diagnosed between January 1st, 2010 and December 31st, 2013 in Spanish rheumatology departments were included. From every centre, 19 patients were randomly chosen from a computerized anonymized list provided by every department. Independent auditors assessed the CRs, verifying the fulfilling of the quality criteria included in an assessment tool specifically developed for this project. The study was approved by the ethic committees of every participant hospital. Descriptive statistics were used for the presentation of the results.

Results:

A total of 254 CRs from 14 rheumatology departments were included. An explicit assessment of the disease activity as a determinant element considered to choose the therapy was recorded in 32% of the CRs. An optimal escalation of methotrexate dose was registered in 77% of the cases. Use of a composite disease activity score (DAS28, SDAI, CDAI) was reported in 88% of the cases. Disease activity monitoring every 6-8 months after reaching the therapeutic target was recorded in 57% of the cases. In 96 % of the cases, the clinicians had registered patient´s comorbidities and these associated conditions had been considered in planning the therapeutic approach and objective. In only 3.8 % of the CRs, visits every 4 weeks using a composite activity score had been reported during the early stage while trying to reach remission after diagnosis. Starting a DMARD in the first two weeks after diagnosis was recorded in only 30 % of the cases.

Conclusion:

Currently, the implementation of the “treat to target” strategy is scarcely registered in clinical records of patients diagnosed with RA in Spanish rheumatology departments.


Disclosure: J. L. Andreu, None; M. A. Martin, None; H. Corominas, None; J. J. Perez Venegas, None; J. A. Roman Ivorra, None; A. Gil, None; F. Sánchez-Alonso, None; T. Jiménez, None; M. A. Sánchez-Ruiz, None.

To cite this abstract in AMA style:

Andreu JL, Martin MA, Corominas H, Perez Venegas JJ, Roman Ivorra JA, Gil A, Sánchez-Alonso F, Jiménez T, Sánchez-Ruiz MA. Quality Assessment in Clinical Management of Patients with Rheumatoid Arthritis. Are We Using the “Treat to Target” Strategy? [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/quality-assessment-in-clinical-management-of-patients-with-rheumatoid-arthritis-are-we-using-the-treat-to-target-strategy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/quality-assessment-in-clinical-management-of-patients-with-rheumatoid-arthritis-are-we-using-the-treat-to-target-strategy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology